Literature DB >> 1894382

Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies.

H Sato1, Y Sato, I Ohishi.   

Abstract

An assay of neutralizing activity against CHO cell-clustering activity, one of the most common assays for anti-pertussis toxin antibodies, did not correlate well with an assay of the protective activities of monoclonal antibodies. A better correlation between neutralization of leukocytosis-promoting or islet-activating activity and mouse protection against aerosol challenge was seen.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1894382      PMCID： PMC258960          DOI： 10.1128/iai.59.10.3832-3835.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  14 in total

1.  Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.

Authors:  J Storsaeter; H Hallander; C P Farrington; P Olin; R Möllby; E Miller
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

2.  Isolation of pertussis toxin subunit proteins by reverse-phase high-performance liquid chromatography and reconstitution of the holotoxin molecule.

Authors:  Y Yamakawa; H Sato; Y Sato
Journal:  Anal Biochem       Date:  1990-02-15       Impact factor: 3.365

3.  Pertussis toxin gene: nucleotide sequence and genetic organization.

Authors:  C Locht; J M Keith
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

4.  Development of a pertussis component vaccine in Japan.

Authors:  Y Sato; M Kimura; H Fukumi
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

5.  Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication.

Authors:  A Nicosia; M Perugini; C Franzini; M C Casagli; M G Borri; G Antoni; M Almoni; P Neri; G Ratti; R Rappuoli
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Protective activities in mice of monoclonal antibodies against pertussis toxin.

Authors:  H Sato; Y Sato
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

7.  Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule.

Authors:  K Nogimori; M Tamura; M Yajima; K Ito; T Nakamura; N Kajikawa; Y Maruyama; M Ui
Journal:  Biochim Biophys Acta       Date:  1984-09-28

8.  Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.

Authors:  M Tamura; K Nogimori; S Murai; M Yajima; K Ito; T Katada; M Ui; S Ishii
Journal:  Biochemistry       Date:  1982-10-26       Impact factor: 3.162

9.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.

Authors:  H Sato; A Ito; J Chiba; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system.

Authors:  H Sato; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441
View more
  22 in total

1.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

2.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

4.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

5.  Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.

Authors:  E M Barry; O Gomez-Duarte; S Chatfield; R Rappuoli; M Pizza; G Losonsky; J Galen; M M Levine
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

6.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells.

Authors:  Scott H Millen; David I Bernstein; Beverly Connelly; Joel I Ward; Swei-Ju Chang; Alison A Weiss
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.

Authors:  Song F Lee; Scott A Halperin; Jennifer B Knight; Aaron Tait
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

9.  Identification of B-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  P H Ibsen; A Holm; J W Petersen; C E Olsen; I Heron
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Identification of human T-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  J W Petersen; A Holm; P H Ibsen; K Hasløv; C Capiau; I Heron
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.